Expert Review of Cardiovascular Therapy最新文献_第2页

Defining persistent atrial fibrillation patient subgroups: predicting responses to repeat ablation procedures to enhance treatment efficacy. 定义持续性心房颤动患者亚组：预测重复消融手术的反应以提高治疗效果。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-25 DOI: 10.1080/14779072.2025.2564132

Neil Bodagh, Kyaw Soe Tun, Mark O'Neill, Steven E Williams

引用次数: 0

Anti-inflammatory strategies for patients with atherosclerotic coronary disease. 冠状动脉粥样硬化性疾病患者的抗炎策略

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-24 DOI: 10.1080/14779072.2025.2564137

Antonino Imbesi, Antonio Greco, Davide Capodanno

{"title":"Anti-inflammatory strategies for patients with atherosclerotic coronary disease.","authors":"Antonino Imbesi, Antonio Greco, Davide Capodanno","doi":"10.1080/14779072.2025.2564137","DOIUrl":"10.1080/14779072.2025.2564137","url":null,"abstract":"Introduction: Atherosclerosis, the primary cause of coronary artery disease (CAD), progresses through subclinical, chronic, and acute phases, culminating in acute myocardial infarction (AMI). Historically viewed as a lipid-driven disorder, it is now recognized as an inflammatory disease. Despite achieving optimal low-density lipoprotein cholesterol reduction, many patients experience residual cardiovascular risk, largely attributed to persistent inflammation.Areas covered: A comprehensive literature search has been performed on PubMed, Web of Science and Cochrane, up to July 2025, with no significant restrictions. The review explores the role of inflammation in plaque progression and destabilization, discusses emerging biomarkers for risk stratification, and summarizes current and investigational anti-inflammatory therapies. Special attention is given to the evolving understanding of acute versus chronic post-AMI inflammation and how this distinction may guide therapeutic strategies.Expert opinion: Anti-inflammatory therapy has reshaped the landscape of cardiovascular prevention, yet challenges remain in patient selection, timing, and target identification. Novel imaging techniques and artificial intelligence-driven risk models offer promising avenues for personalized therapy. Future efforts should focus on precision-based approaches that target detrimental immune activation while preserving reparative processes, ensuring maximal clinical benefit.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":2.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reviewing the use of antiarrhythmic drugs in elderly patients with atrial fibrillation. 老年房颤患者抗心律失常药物的应用综述。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-17 DOI: 10.1080/14779072.2025.2561717

Danilo Menichelli, Gianluca Gazzaniga, Daniele Malatesta, Giordano Di Carlo, Tommaso Brogi, Arianna Pani, Pasquale Pignatelli, Daniele Pastori

{"title":"Reviewing the use of antiarrhythmic drugs in elderly patients with atrial fibrillation.","authors":"Danilo Menichelli, Gianluca Gazzaniga, Daniele Malatesta, Giordano Di Carlo, Tommaso Brogi, Arianna Pani, Pasquale Pignatelli, Daniele Pastori","doi":"10.1080/14779072.2025.2561717","DOIUrl":"10.1080/14779072.2025.2561717","url":null,"abstract":"Introduction: Atrial fibrillation (AF) is the most common arrhythmia in elderly patients. Antiarrhythmic drugs (AADs) are often required for rate/rhythm control and to improve AF-related symptoms. There is limited evidence on the effectiveness and safety of AADs in elderly AF patients.Areas covered: This narrative review focuses on the use of AADs in elderly AF patients, summarizing the different physiology, pharmacokinetics, and pharmacodynamics in the older age. Furthermore, the evidence from clinical studies on AADs pointing up data on safety and effectiveness in the elderly was summarized.Expert opinion: Although AADs represent a cornerstone for symptom relief in patients with AF, these drugs did not show a clinical net benefit compared to rate control, with a potentially increased risk of complications and hospitalizations. Considering also the different pharmacokinetics and the concomitant comorbidities and treatments that characterize older patients, the administration of these drugs should be reserved for selected patients with a high burden of AF-related symptoms.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What impact could tirzepatide have on major cardiovascular complications in patients with obstructive sleep apnea? 替西肽对阻塞性睡眠呼吸暂停患者的主要心血管并发症有何影响？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-16 DOI: 10.1080/14779072.2025.2561067

Avnee J Kumar, Samantha Scroggie, Tia De Sarkar, Mark Hepokoski, Atul Malhotra

引用次数: 0

The staging of cardiac damage for mitral regurgitation: ready for prime time? 二尖瓣返流的心脏损伤分期：准备好了吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-13 DOI: 10.1080/14779072.2025.2561070

Michail Penteris, Anastasia Kalogirou, Konstantinos Lampropoulos

{"title":"The staging of cardiac damage for mitral regurgitation: ready for prime time?","authors":"Michail Penteris, Anastasia Kalogirou, Konstantinos Lampropoulos","doi":"10.1080/14779072.2025.2561070","DOIUrl":"10.1080/14779072.2025.2561070","url":null,"abstract":"Introduction: Mitral regurgitation (MR) is a progressive valvular heart disease (VHD) with significant morbidity and mortality, particularly in older adults. Current guidelines rely primarily on symptom status and LV function to guide intervention, which may underestimate disease severity, especially in asymptomatic patients.Areas covered: A comprehensive literature search was conducted in PubMed/Medline, Scopus and EMBASE databases for articles until March 2025. This review discusses MR severity grading and introduces the concept of extra-mitral cardiac damage staging, adapted from models used in aortic stenosis. It highlights the application of this staging to both primary and secondary MR, detailing how structural and functional deterioration beyond the mitral valve, such as involvement of the LV, left atrium, pulmonary vasculature, and right ventricle, correlates with outcomes.Expert opinion: Cardiac damage staging offers a practical, echocardiography-based tool for personalized risk assessment. It allows for the earlier identification of high-risk patients and may shift intervention timing, especially for transcatheter therapies. Despite some variability in staging definitions, its integration into clinical practice could enhance patient stratification and management. Future research should aim to standardize criteria and assess its role in prospective trials, advancing the field toward precision care in VHD.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of stress-induced hyperglycemia in acute coronary syndromes: pathophysiology, novel markers and clinical implications. 应激性高血糖在急性冠状动脉综合征中的作用：病理生理学、新标志物和临床意义。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-13 DOI: 10.1080/14779072.2025.2561068

Marios G Bantidos, Nikolaos Stalikas, Barbara Fyntanidou, Ioannis Skalidis, Alexandra Arvanitaki, Christos Kofos, Aikaterini Apostolopoulou, George Giannopoulos, Efstratios Karagiannidis

{"title":"The role of stress-induced hyperglycemia in acute coronary syndromes: pathophysiology, novel markers and clinical implications.","authors":"Marios G Bantidos, Nikolaos Stalikas, Barbara Fyntanidou, Ioannis Skalidis, Alexandra Arvanitaki, Christos Kofos, Aikaterini Apostolopoulou, George Giannopoulos, Efstratios Karagiannidis","doi":"10.1080/14779072.2025.2561068","DOIUrl":"10.1080/14779072.2025.2561068","url":null,"abstract":"Introduction: Stress-Induced Hyperglycemia (SIH) represents a transient increase in blood glucose levels triggered by acute physiological stress, frequently observed in patients with Acute Coronary Syndrome (ACS). It is linked to adverse outcomes, including higher mortality and an increased risk of Major Adverse Cardiac and Cerebrovascular Events (MACCE). Despite this, SIH remains inadequately defined and underappreciated in clinical risk assessment and patient management.Areas covered: This narrative review delves into the mechanistic underpinnings of SIH in ACS (neuroendocrine, metabolic and inflammatory pathways). Evidence on current SIH markers [including the Stress-Hyperglycemia Ratio (SHR), Admission Blood Glucose, Glycemic Gap, and Glycemic Variability] was identified through searches of PubMed/MEDLINE for English-language human studies published between January 2017 and May 2025 (certain seminal earlier studies were also retained), with a focus on key subpopulations (diabetes, non-diabetes, and MINOCA). Particular emphasis is placed on SHR as a ratio of acute to chronic hyperglycemia with expanding prognostic applications.Expert opinion: SIH is a multifaceted phenomenon, superiorly reflected by dynamic indices like SHR rather than traditional measures. Further research into the mechanisms linking SIH with adverse outcomes could lay the groundwork for interventional trials, ultimately reshaping ACS patient risk-stratification and management.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-20"},"PeriodicalIF":2.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining the role of leadless pacemaker patient selection in light of technological advances and real-world evidence. 根据技术进步和现实证据重新定义无导线起搏器患者选择的作用。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-12 DOI: 10.1080/14779072.2025.2561069

Gianfranco Mitacchione, Emiliano Calvi, Pietro Igor Ponchia, Gianmarco Arabia, Antonio Curnis

引用次数: 0

Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions. 康瑞洛经皮冠状动脉介入治疗：证据进展、临床应用和未来方向。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-12 DOI: 10.1080/14779072.2025.2544816

Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, Elisabetta Moscarella, Natale Guarnaccia, Antonio Capolongo, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Gianmaria Scherillo, Pierre Sabouret, Daniele Giacoppo, Mattia Galli, Giuseppe Gargiulo, Giovanni Esposito, Marco Valgimigli, Dominick J Angiolillo, Paolo Calabrò

{"title":"Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions.","authors":"Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, Elisabetta Moscarella, Natale Guarnaccia, Antonio Capolongo, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Gianmaria Scherillo, Pierre Sabouret, Daniele Giacoppo, Mattia Galli, Giuseppe Gargiulo, Giovanni Esposito, Marco Valgimigli, Dominick J Angiolillo, Paolo Calabrò","doi":"10.1080/14779072.2025.2544816","DOIUrl":"10.1080/14779072.2025.2544816","url":null,"abstract":"Introduction: Cangrelor is the only parenteral P2Y12 receptor antagonist currently recommended for the prevention of periprocedural thrombotic complications in P2Y12 inhibitor-naïve patients undergoing percutaneous coronary intervention (PCI).Areas covered: This review provides a comprehensive analysis of the pharmacological properties and administration strategies of cangrelor in PCI, summarizes the latest evidence from clinical trials and real-world studies, and discusses potential future directions for its application in clinical practice. Literature search was conducted using PubMed up to May 2025.Expert opinion: Cangrelor provides rapid platelet inhibition following an intravenous bolus, and its short half-life ensures predictable pharmacokinetic profile, facilitating perioperative management. The CHAMPION program demonstrated that cangrelor significantly reduces early ischemic events, including myocardial infarction and stent thrombosis, compared with clopidogrel in patients undergoing PCI. Since its approval, several clinical trials and observational studies have further evaluated the efficacy and safety of cangrelor and its optimal use. The adoption of cangrelor in catheterization laboratories worldwide remains inconsistent, with misuse being frequently reported. Drug-related costs along with concerns surrounding drug interaction when switching to oral P2Y12 inhibitors, limited safety data in high-risk populations and lack of evidence on the comparison against ticagrelor or prasugrel may contribute to its restricted utilization in clinical practice.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"507-519"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ebstein anomaly update: the evolution of care and the revolution of surgical strategy. Ebstein异常更新：护理的演变和手术策略的革命。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-16 DOI: 10.1080/14779072.2025.2544817

Tamer Jamal, Elizabeth H Stephens, Nathan Taggart, M Yasir Qureshi, Elena A Swan, Jeffrey R Weatherhead, Joseph A Dearani

引用次数: 0

The association between the compliance of prescriptions with treatment guidelines and long-term survival after acute coronary syndrome: results from the ERICO study. 急性冠状动脉综合征后处方与治疗指南的依从性与长期生存之间的关系：来自ERICO研究的结果

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-14 DOI: 10.1080/14779072.2025.2544812

Rafael C O Santos, Isabela M Bensenor, Paulo A Lotufo, Alessandra C Goulart, Flávia L Daher, Antonio C P Lima, Itamar S Santos

{"title":"The association between the compliance of prescriptions with treatment guidelines and long-term survival after acute coronary syndrome: results from the ERICO study.","authors":"Rafael C O Santos, Isabela M Bensenor, Paulo A Lotufo, Alessandra C Goulart, Flávia L Daher, Antonio C P Lima, Itamar S Santos","doi":"10.1080/14779072.2025.2544812","DOIUrl":"10.1080/14779072.2025.2544812","url":null,"abstract":"Background: Compliance of prescriptions with treatment guidelines (CPTG) after an acute coronary syndrome (ACS) is poorly studied. We studied CPTG index levels in ERICO cohort over three years and its association with long-term mortality.Research design and methods: We analyzed data from 961 ERICO participants who were discharged after an ACS event. Medication information was obtained at discharge, 30 days 180 days, and yearly after the index event. The CPTG index was defined as the proportion of evidence-based medications for post-ACS care (anti-platelets, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers, and statins), a patient's prescription had. We verified the association between CPTG index and survival using adjusted Cox regression.Results: The median age was 62 years, and 41% were female. At 30 days, the proportion of individuals with CPTG index = 1.0 decreased to the lowest values observed (23.4%), followed by a partial recovery (40.1% at 180 days). CPTG index was significantly associated with better survival (Hazard Ratio for a 0.1-point increase: 0.92; 95% confidence interval:0.87-0.96).Conclusions: The CPTG index was significantly associated with long-term survival. The expressive drop in CPTG index values 30 days after discharge suggests that targeted actions might be necessary to ensure timely healthcare access in this population.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"577-583"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0